"Tryptamines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Decarboxylated monoamine derivatives of TRYPTOPHAN.
| Descriptor ID |
D014363
|
| MeSH Number(s) |
D02.092.211.215.801 D03.633.100.473.914
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tryptamines".
Below are MeSH descriptors whose meaning is more specific than "Tryptamines".
This graph shows the total number of publications written about "Tryptamines" by people in this website by year, and whether "Tryptamines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tryptamines" by people in Profiles.
-
Bergh MS, Bogen IL, Grafinger KE, Huestis MA, ?iestad ?ML. Metabolite markers for three synthetic tryptamines N-ethyl-N-propyltryptamine, 4-hydroxy-N-ethyl-N-propyltryptamine, and 5-methoxy-N-ethyl-N-propyltryptamine. Drug Test Anal. 2024 Dec; 16(12):1544-1557.
-
Carlier J, Malaca S, Huestis MA, Tagliabracci A, Tini A, Busard? FP. Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations. Expert Opin Drug Metab Toxicol. 2022 Dec; 18(12):831-840.
-
Cowan RP, Marmura MJ, Diener HC, Starling AJ, Schim J, Hirman J, Brevig T, Cady R. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. J Headache Pain. 2022 Sep 06; 23(1):115.
-
Nahas SJ, Hindiyeh N, Friedman DI, Elbuluk N, Kellerman DJ, Foreman PK, Schmidt P. Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine. J Headache Pain. 2021 May 17; 22(1):37.
-
Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busard? FP, Huestis MA. Toxicology and Analysis of Psychoactive Tryptamines. Int J Mol Sci. 2020 Dec 04; 21(23).
-
Merry DE. Attacking the flank: targeting new pathways in SBMA. Nat Med. 2012 Oct; 18(10):1461-3.
-
Nahas SJ, Silberstein SD. Triptans: actions and reactions. Headache. 2008 Apr; 48(4):611-3.
-
Bell CF, Foley KA, Barlas S, Solomon G, Hu XH. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study. Clin Ther. 2006 Jun; 28(6):872-80.
-
Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol. 2002 May; 42(5):520-7.
-
Mayo KW, Osterhaus JT. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings. Am J Manag Care. 2002 Feb; 8(3 Suppl):S85-93.